Innovent Biologics Reports Over 40% Revenue Growth in Q1 2025

An announcement from Innovent Biologics ( (HK:1801) ) is now available.

Innovent Biologics reported a significant increase in product revenue for the first quarter of 2025, exceeding RMB2.4 billion, marking a growth of over 40% year-on-year. The company launched four new products, including Dovbleron, Limertinib, and Jaypirca in oncology, and SYCUME in general biomedicine, which contributed to the revenue growth. The inclusion of SINTBILO in the National Reimbursement Drug List and the launch of SYCUME for thyroid eye disease are seen as new growth drivers. Innovent’s strategic focus on sustainable growth and global innovation positions it for continued expansion in the biopharmaceutical industry.

More about Innovent Biologics

Innovent Biologics, Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of oncology and general biomedicine products. The company is a leading brand in oncology treatment and is committed to sustainable growth and global innovation, with a robust pipeline in oncology, cardiovascular and metabolism, autoimmune, and ophthalmology sectors.

YTD Price Performance: 30.46%

Average Trading Volume: 13,529

Technical Sentiment Signal: Sell

Current Market Cap: $11.35B

For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.